Skip to Content

Lipella Pharmaceuticals Inc Ordinary Shares LIPO

Morningstar Rating
$0.72 +0.01 (1.54%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

LIPO is trading at a 69% discount.
Price
$0.72
Fair Value
$6.98
Uncertainty
Extreme
1-Star Price
$25.79
5-Star Price
$6.25
Economic Moat
Ltqc
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LIPO is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.71
Day Range
$0.720.72
52-Week Range
$0.652.70
Bid/Ask
$0.00 / $2.30
Market Cap
$5.06 Mil
Volume/Avg
19,631 / 66,427

Key Statistics

Price/Earnings (Normalized)
Price/Sales
9.61
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
7

Valuation

Metric
LIPO
Price/Earnings (Normalized)
Price/Book Value
1.39
Price/Sales
9.61
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
LIPO
Quick Ratio
8.63
Current Ratio
8.90
Interest Coverage
−437.50
Quick Ratio
LIPO

Profitability

Metric
LIPO
Return on Assets (Normalized)
−79.72%
Return on Equity (Normalized)
−96.09%
Return on Invested Capital (Normalized)
−93.03%
Return on Assets
LIPO
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRPygqrknltXlxc$557.8 Bil
VRTX
Vertex Pharmaceuticals IncKqrsxfbDyfym$103.3 Bil
REGN
Regeneron Pharmaceuticals IncLytydllbrPrrtmqf$98.8 Bil
MRNA
Moderna IncPmggwcplKbzlh$38.8 Bil
ARGX
argenx SE ADRXtdpwlblnWvsbd$21.3 Bil
BNTX
BioNTech SE ADRMplkscwtSrqy$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncSdrrqpzbwVplcss$18.4 Bil
BMRN
Biomarin Pharmaceutical IncVtkskmdxtWyypw$17.0 Bil
RPRX
Royalty Pharma PLC Class APdftgyncvNckljpb$12.4 Bil
INCY
Incyte CorpZfkpvcxFksyf$11.9 Bil

Sponsor Center